The U.S. Food and Drug Administration (FDA) has outlined its ongoing efforts to ensure the quality, safety, and availability of generic medicines while continuing to support patient access to more affordable treatment options.
According to the agency, recent scientific and regulatory advancements have enabled the approval of increasingly complex generic products. During the past year, the FDA approved the first generic versions of complex inhalation products, including Flovent and QVAR, as well as the first generic version of the GLP-1 receptor agonist Saxenda. In addition, the agency updated several product-specific guidances on 21 May 2026 to help reduce the need for costly and lengthy clinical studies for generic inhalation products.
The Role of Generic Medicines in Healthcare Access
The FDA emphasized the significant role of generic medicines in improving access to treatment in the United States. Generic products account for more than 90% of prescriptions dispensed nationwide while representing less than 13% of prescription drug spending.
The agency noted that generic medicines have generated savings exceeding $3 trillion over the past decade, helping reduce financial burdens on patients and supporting access to essential therapies.
At the same time, the FDA noted that public concerns regarding generic drug quality and supply chains can influence confidence in these products. While welcoming public scrutiny, the agency emphasized that concerns should be considered alongside the extensive oversight systems used to monitor generic drug quality and safety.
Manufacturing Standards and Quality Requirements
The FDA explained that both brand-name and generic medicines are subject to the same quality expectations.
Before approval, manufacturers must demonstrate compliance with current Good Manufacturing Practice (CGMP) requirements regardless of whether production takes place in the United States or abroad. Manufacturers are also expected to test drug batches against approved specifications before products are released for patient use.
The agency highlighted its Quality Management Maturity Program, which encourages manufacturers to strengthen quality management practices beyond minimum regulatory requirements. The program is intended to support a stronger quality culture, identify opportunities for improvement, and contribute to a more reliable pharmaceutical supply chain.
Risk-Based Inspection Approach
FDA oversight includes routine risk-based inspections of manufacturing facilities.
The agency noted that inspection activities were significantly affected during the COVID-19 pandemic. To maintain oversight, the FDA expanded the use of remote regulatory assessments, records requests, and collaboration with trusted international regulatory partners through mutual recognition agreements.
According to the agency, inspection coverage has continued to recover and is approaching pre-pandemic levels. The FDA also reported increasing unannounced inspections at foreign manufacturing facilities to address historical differences between domestic and foreign inspection practices.
Supporting Domestic Pharmaceutical Manufacturing
The FDA reiterated its support for strengthening pharmaceutical manufacturing capacity within the United States.
The agency stated that domestic manufacturing plays an important role in improving supply chain resilience and reducing vulnerabilities associated with dependence on a limited number of geographic regions.
To support this objective, the FDA has introduced initiatives such as the PreCheck Pilot Program, which is designed to facilitate the development of new domestic manufacturing facilities. The agency also highlighted the FDA ANDA Prioritization Pilot, which accelerates review activities for generic drug companies that test and manufacture their products in the United States.
Post-Approval Monitoring and Product Surveillance
The FDA continues to monitor product quality after approval through a comprehensive surveillance framework that incorporates quality reports, adverse event information, inspection findings, laboratory testing results, manufacturing metrics, and supply chain data.
The agency explained that this information is used to identify and investigate potential quality concerns. When safety or quality signals emerge, the FDA may conduct further evaluations that include inspections, product testing, or additional analyses.
The FDA also performs targeted testing of marketed drug products using a risk-based approach. Due to resource limitations, testing activities focus on products with higher risk profiles or products associated with credible quality concerns.
In addition, the agency maintains adverse event monitoring systems to identify potential safety concerns or issues related to product performance.
Third-Party Testing and Quality Reporting
The FDA acknowledged the growing role of third-party testing laboratories within the pharmaceutical quality landscape.
While the agency supports appropriately validated testing methods, it also expressed concern regarding the use of testing approaches that may generate inaccurate results or unsupported conclusions.
To strengthen regulatory monitoring, the FDA encourages reporting suspected generic drug quality or safety issues through its SmartHub reporting system.
According to the agency, although generic medicines account for approximately 90% of prescriptions dispensed in the United States, they have represented only 40% of product quality defect reports received by the FDA.
Looking Ahead
The FDA stated that oversight of generic medicines involves collaboration across multiple agency offices responsible for generic drugs, pharmaceutical quality, compliance, surveillance, and epidemiology.
The agency also reported progress in addressing drug shortages, noting that only four new shortages were recorded in 2025 compared with a peak of 251 shortages in 2011.
Moving forward, the FDA reaffirmed its commitment to ensuring that all medicines marketed in the United States—whether brand-name or generic, domestically produced or imported—continue to meet established quality standards while supporting access to affordable treatment options.
For More Information
For the complete FDA Voices article and original details, please refer to the official source:
Original Source: https://www.fda.gov/news-events/fda-voices/ensuring-quality-and-access-fdas-approach-generic-drug-oversight
How Baupharma Can Support Generic Drug Regulatory Activities
As regulatory expectations for generic medicines continue to evolve, pharmaceutical companies require strategic support to navigate submission requirements, quality documentation, lifecycle management, and interactions with health authorities efficiently.
Baupharma’s Regulatory Affairs services provide end-to-end support for generic drug development and registration, including regulatory intelligence, dossier preparation, submission management, lifecycle maintenance, and global regulatory compliance.
Learn more about our Regulatory services: https://www.baupharma.com/services-categories/regulatory-affairs/#Regulatory-affairs-services
